Agios Pharmaceuticals (AGIO) Accounts Payables (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Accounts Payables data on file, last reported at $16.3 million in Q2 2026.

• Quarterly Accounts Payables fell 6.77% year-over-year to $16.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $16.3 million (down 6.77% YoY) and the FY2025 annual result came in at $18.4 million, up 10.29% from the prior year.
• Accounts Payables climbed to $16.3 million in Q2 2026, from $13.7 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $19.6 million in Q3 2025 to a low of $7.8 million in Q2 2022.
• A 5-year average of $13.7 million and a median of $13.5 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables plunged 77.45% — and 2025, when it jumped 74.71%.
• Tracing AGIO's Accounts Payables over 5 years: stood at $18.6 million in 2022, then sank by 47.46% to $9.8 million in 2023, then surged by 70.17% to $16.6 million in 2024, then advanced by 10.29% to $18.4 million in 2025, then slipped by 10.95% to $16.3 million in 2026.
• The last three Accounts Payables figures came in at $16.3 million (Q2 2026), $13.7 million (Q1 2026), and $18.4 million (Q4 2025), per Business Quant data.